Menu

Zika’s Effects on Babies Can Show Up Later

The CDC finds one in seven children exposed to the virus in utero experiences health problems by age one.

Aug 7, 2018
Kerry Grens

ABOVE: © ISTOCK, AYWAN88

Around 14 percent of babies whose mothers contracted Zika while pregnant ended up with a birth defect, developmental abnormality, or both, according a report released by the US government today (August 7). Some of the symptoms didn’t show up right away when the babies were born, but emerged in later testing.

“The full range of long-term health problems caused by Zika will remain unknown until these babies mature,” according to a summary of the report from the Centers for Disease Control and Prevention (CDC).

The agency collected health data on 1,450 babies at least one year old who were exposed to Zika in utero and born in a US territory. Six percent of the children had a Zika-associated birth defect, but others’ symptoms showed up later in life. Among 822 babies who did not have a birth defect, 14 had a brain abnormality that was revealed in neuroimaging.

See “Mouse Pups Infected With Zika Show Symptoms Into Adulthood

“That happened because their brain was not growing and developing properly” due to the virus, Margaret Honein, director of the Division of Congenital and Developmental Disorders at the CDC, tells NPR.

In the US and its territories, reports of Zika infections tapered off at the beginning of 2017, with very few cases popping up since then. However, this likely isn’t the end of Zika, and outbreaks may re-emerge.

“I think the bottom line is that the Zika story is not over,” Honein tells The Washington Post. “People may feel like it’s behind us. For these children, it’s not over, and we need to know as much as possible so that we can be prepared” for a future outbreak.

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.